Jfs Wealth Advisors Has Raised Comcast New (CMCSA) Stake; 4 Bullish Analysts Covering Corcept Therapeutics (CORT)

December 7, 2017 - By Richard Conner

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 7 analyst reports since February 2, 2017 according to SRatingsIntel. Ladenburg Thalmann initiated Corcept Therapeutics Incorporated (NASDAQ:CORT) rating on Thursday, February 2. Ladenburg Thalmann has “Buy” rating and $14 target. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Thursday, August 24 with “Buy” rating. Stifel Nicolaus maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) rating on Friday, November 3. Stifel Nicolaus has “Buy” rating and $25.0 target. The firm earned “Buy” rating on Wednesday, October 11 by Piper Jaffray. Piper Jaffray maintained it with “Buy” rating and $24.0 target in Friday, September 8 report. See Corcept Therapeutics Incorporated (NASDAQ:CORT) latest ratings:

03/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $25.0 Maintain
11/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
08/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
31/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $20 Initiates Coverage On
24/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $18.0 Maintain
18/07/2017 Broker: Ladenburg Rating: Buy New Target: $20.0000

Jfs Wealth Advisors Llc increased Comcast Corp New (CMCSA) stake by 80.22% reported in 2017Q2 SEC filing. Jfs Wealth Advisors Llc acquired 19,398 shares as Comcast Corp New (CMCSA)’s stock rose 3.16%. The Jfs Wealth Advisors Llc holds 43,578 shares with $1.70M value, up from 24,180 last quarter. Comcast Corp New now has $177.56B valuation. The stock decreased 1.66% or $0.64 during the last trading session, reaching $37.99. About 19.39 million shares traded. Comcast Corporation (NASDAQ:CMCSA) has risen 28.96% since December 7, 2016 and is uptrending. It has outperformed by 12.26% the S&P500.

Among 29 analysts covering Comcast Corporation (NASDAQ:CMCSA), 24 have Buy rating, 1 Sell and 4 Hold. Therefore 83% are positive. Comcast Corporation had 66 analyst reports since July 27, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Friday, September 8 report. The rating was maintained by UBS on Friday, July 24 with “Buy”. As per Thursday, July 23, the company rating was maintained by Pivotal Research. The stock of Comcast Corporation (NASDAQ:CMCSA) has “Sector Weight” rating given on Friday, January 27 by Pacific Crest. The stock of Comcast Corporation (NASDAQ:CMCSA) earned “Buy” rating by Moffett Nathanson on Tuesday, September 12. Suntrust Robinson initiated the stock with “Neutral” rating in Wednesday, November 11 report. On Friday, August 19 the stock rating was maintained by Telsey Advisory Group with “Outperform”. The stock of Comcast Corporation (NASDAQ:CMCSA) has “Outperform” rating given on Wednesday, October 28 by RBC Capital Markets. The stock of Comcast Corporation (NASDAQ:CMCSA) earned “Buy” rating by Pivotal Research on Monday, June 26. The rating was maintained by Jefferies with “Buy” on Monday, December 19.

Investors sentiment decreased to 1.01 in Q2 2017. Its down 11.82, from 12.83 in 2017Q1. It dropped, as 68 investors sold CMCSA shares while 503 reduced holdings. 110 funds opened positions while 468 raised stakes. 3.69 billion shares or 50.72% less from 7.49 billion shares in 2017Q1 were reported. Smithfield holds 0.23% or 40,546 shares in its portfolio. Atalanta Sosnoff Capital Limited Liability invested 2.53% of its portfolio in Comcast Corporation (NASDAQ:CMCSA). E&G Advisors Lp has 61,162 shares for 1.14% of their portfolio. Wellington Shields & Lc accumulated 19,992 shares. Hutchin Hill LP holds 259,800 shares or 0.34% of its portfolio. Meritage Port holds 0.03% of its portfolio in Comcast Corporation (NASDAQ:CMCSA) for 6,940 shares. Fdx Advisors stated it has 123,442 shares or 0.14% of all its holdings. Valley Advisers Inc has invested 0.07% in Comcast Corporation (NASDAQ:CMCSA). Coastline Tru holds 1.57% or 222,756 shares in its portfolio. Riverhead Mgmt Lc holds 97,916 shares or 0.19% of its portfolio. Oakbrook Invs Ltd Llc accumulated 89,014 shares or 0.23% of the stock. Td Asset Management Inc invested 0.59% in Comcast Corporation (NASDAQ:CMCSA). Moreover, Chicago Equity Ptnrs Ltd Liability Company has 0.59% invested in Comcast Corporation (NASDAQ:CMCSA). Sky Invest Group Limited Liability Corporation has invested 0.45% in Comcast Corporation (NASDAQ:CMCSA). Foxhaven Asset Limited Partnership invested 4.38% of its portfolio in Comcast Corporation (NASDAQ:CMCSA).

Jfs Wealth Advisors Llc decreased Ishares Tr (IJH) stake by 2,616 shares to 102,110 valued at $17.76 million in 2017Q2. It also reduced Vanguard Charlotte Fds (BNDX) stake by 7,670 shares and now owns 9,889 shares. Schwab Strategic Tr (SCHZ) was reduced too.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.89 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 57.03 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

The stock increased 2.04% or $0.33 during the last trading session, reaching $16.54. About 989,457 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since December 7, 2016 and is uptrending. It has outperformed by 108.11% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com